Overall, our study demonstrates that therapeutic molecules based on itaconate could have positive therapeutical implications for CAPS with p.R262W, p.D305 N and p.T350M variants that control inflammatory flares acting on different levels, namely by reducing Il1b expression and preventing mutant NLRP3 autoactivation. This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.